Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
H.ChenC
The EMPA-REG and CANVAS trials showed that the SGLT-2i empagliflozin and SGLT-1/2i canagliflozin reduced the risk of MACE in T2D patients with or at high risk of CVD by 14%, while the SGLT-2i dapagliflozin did not significantly reduce the risk of MACE, possibly due to the difference in population (approximately 60% with no established ASCVD) between previous trials and strict exclusion criteria
This avoids the growth of fungi and bacteria in the solution until the expiry date when stored adequately
Advances in Experimental Medicine and Biology, vol 1301
US$ 26.25
US$ 24.02
US$ 28.08
US$ 23.41
